Directorate of Contracting, Fitzsimons Army Medical Center, ATTN: MCHG-DCC, Aurora, CO 80045-5001

65 -- NOTICE OF INTENT TO AWARD A NON-COMPETITIVE CONTRACT TO DIAGNOSTIC MARKETING CORPORATION FOR COAGULATION REAGENTS SOL DADA03-95-R-0037 DUE 091495 POC Jackie Scripture, Contract Specialist, (303)361-3315 or Emily J. Mathis, Contracting Officer, (303)361-3315. The Government plans to issue a solicitation to Diagnostic Marketing Corporation to purchase, under a requirements contract and on a sole source basis, coagulation reagents for use with an Organon Teknika MDA-180 system and a STAT RA-4 system. The following reagents, etc., are required, MDA Platelin L/CaCL2, MDA Fibriquick, MDA Thromboquick, MDA Verify 1, MDA Verify 2, MDA Verify 3, MDA Verify Ref. Plasma, MDA Verical Set, MDA Cuvettes, MDA Imadazole Buffer, MDA Probe Cleaner, and MDA Reagent Water. The reagents and supplies are to be used for performance of activate prothrombin times, activiated partial thromboplastin times, fibrinogens, Thrombin times, and associated coagulation tests by the Hematology Section, Department of Pathology, Fitzsimons Army Medical Center. The following represent some, though not all, of the most critical minimum requirements of this acquisition: Lot numbers must have 6 - 12 month outdate upon arrival. PT and APTT reagents must contain dye whose value is appropriate to the MDA-180 and RA-4 coagulation systems. Each reagent must react one with another to accurately reflect he patient's normal value range significantly (+0.5sec). The controls offered must be stable for 24 hours after dilution and only adsorbed controls are acceptable. The APTT reagents offered cannot contain kaolin or kaolin-like activators; the activator must be micronized silica with no coating. Reagents must possess a low sensitivity to heparin in the threshold range but high sensitibity to heparin in the therapeutic range as well as consistency lot to lot. The sensitivity to factor decreases must bhe at least 40%; 25% for factor VIII, i.e., the reagent must indicate an abnormal value when a 40% factor deficiency exists. The APTT reagent must posses a high sensitivity to lupus-like inhibitors (lupus anticoagulant). The contractor must maintain a local stockage and be capable of replacing reagents within hours (usually within two - four hours) of notification of a problem due to specimen deterioration. And, the offeror must have sufficient customers in the Denver Metro Area that so Fitzsimons could be included in a quality control program with at least three other local members which all utilize the same offeror's lot of reagents and the same instruments. The period of performance will be October 1, 1995, or date of award if later, through September 39, 1996, with a one-year option period. The solicitation is to be issued o/a August 14, 1995. Firms other than Diagnostic Marketing Corporation interested in receiving a copy of the solicitation must provide EVIDENCE OF CAPABILITY to meet at least the minimum requirements reflected herein. Requests for solicitations not accompanied by evidence of capability will not be honored. All requests for solicitations must be submitted in writing. See Numbered Note(s): 22. (0198)

Loren Data Corp. http://www.ld.com (SYN# 0564 19950718\65-0001.SOL)